SG11201701116XA - Macrocyclic rip2 kinase inhibitors - Google Patents
Macrocyclic rip2 kinase inhibitorsInfo
- Publication number
- SG11201701116XA SG11201701116XA SG11201701116XA SG11201701116XA SG11201701116XA SG 11201701116X A SG11201701116X A SG 11201701116XA SG 11201701116X A SG11201701116X A SG 11201701116XA SG 11201701116X A SG11201701116X A SG 11201701116XA SG 11201701116X A SG11201701116X A SG 11201701116XA
- Authority
- SG
- Singapore
- Prior art keywords
- kinase inhibitors
- rip2 kinase
- macrocyclic
- macrocyclic rip2
- inhibitors
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 101150021296 rip2 gene Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185130 | 2014-09-17 | ||
| PCT/EP2015/071347 WO2016042087A1 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic rip2 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701116XA true SG11201701116XA (en) | 2017-03-30 |
Family
ID=51687776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701116XA SG11201701116XA (en) | 2014-09-17 | 2015-09-17 | Macrocyclic rip2 kinase inhibitors |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10676486B2 (enExample) |
| EP (1) | EP3194407B1 (enExample) |
| JP (1) | JP6736545B2 (enExample) |
| KR (1) | KR102563829B1 (enExample) |
| CN (1) | CN106687464B (enExample) |
| AU (1) | AU2015316799B2 (enExample) |
| BR (1) | BR112017004035B1 (enExample) |
| CA (1) | CA2958782C (enExample) |
| DK (1) | DK3194407T3 (enExample) |
| EA (1) | EA032872B1 (enExample) |
| ES (1) | ES2763344T3 (enExample) |
| HR (1) | HRP20192334T1 (enExample) |
| HU (1) | HUE048518T2 (enExample) |
| IL (1) | IL250544B (enExample) |
| LT (1) | LT3194407T (enExample) |
| MX (1) | MX376087B (enExample) |
| MY (1) | MY186523A (enExample) |
| PL (1) | PL3194407T3 (enExample) |
| PT (1) | PT3194407T (enExample) |
| SA (1) | SA517381087B1 (enExample) |
| SG (1) | SG11201701116XA (enExample) |
| SI (1) | SI3194407T1 (enExample) |
| TW (1) | TWI709563B (enExample) |
| UA (1) | UA121315C2 (enExample) |
| WO (1) | WO2016042087A1 (enExample) |
| ZA (1) | ZA201701331B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102719387B1 (ko) * | 2017-01-26 | 2024-10-21 | 한미약품 주식회사 | 이미다조피리다진 화합물 |
| TW202140499A (zh) | 2020-01-31 | 2021-11-01 | 法商腫瘤設計公司 | 巨環ｒｉｐ２－激酶抑制劑 |
| JP2025532532A (ja) * | 2022-09-07 | 2025-10-01 | 蘇州朗睿生物医薬有限公司 | 大環状イミダゾ［１，２－ｂ］ピリダジン誘導体並びにその調製方法及び用途 |
| CN120500490A (zh) * | 2023-01-03 | 2025-08-15 | 广东新契生物医药科技有限公司 | 作为usp1抑制剂的大环化合物 |
| WO2025212514A2 (en) * | 2024-04-02 | 2025-10-09 | Interline Therapeutics, Inc. | Methods of treating inflammatory diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| DK0721331T3 (da) | 1993-10-01 | 2002-02-11 | Astrazeneca Ab | Fremgangsmåde |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| MY146474A (en) * | 2006-11-06 | 2012-08-15 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| ES2628418T3 (es) * | 2010-05-20 | 2017-08-02 | Array Biopharma, Inc. | Compuestos macrocíclicos como inhibidores de la TRK cinasa |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| TWI547494B (zh) * | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| JP6046728B2 (ja) * | 2011-09-30 | 2016-12-21 | オンコデザイン エス．ア． | 大環状ｆｌｔ３キナーゼ阻害剤 |
| BR112014007654A8 (pt) | 2011-09-30 | 2018-06-12 | Ipsen Pharma | Inibidores de lrrk2 quinase macrocíclicos. |
-
2015
- 2015-09-17 KR KR1020177010128A patent/KR102563829B1/ko active Active
- 2015-09-17 EA EA201790609A patent/EA032872B1/ru unknown
- 2015-09-17 DK DK15766800.5T patent/DK3194407T3/da active
- 2015-09-17 SI SI201531050T patent/SI3194407T1/sl unknown
- 2015-09-17 UA UAA201703558A patent/UA121315C2/uk unknown
- 2015-09-17 LT LTEP15766800.5T patent/LT3194407T/lt unknown
- 2015-09-17 WO PCT/EP2015/071347 patent/WO2016042087A1/en not_active Ceased
- 2015-09-17 CA CA2958782A patent/CA2958782C/en active Active
- 2015-09-17 HU HUE15766800A patent/HUE048518T2/hu unknown
- 2015-09-17 MX MX2017003469A patent/MX376087B/es active IP Right Grant
- 2015-09-17 TW TW104130751A patent/TWI709563B/zh active
- 2015-09-17 JP JP2017514486A patent/JP6736545B2/ja active Active
- 2015-09-17 US US15/505,976 patent/US10676486B2/en active Active
- 2015-09-17 PL PL15766800T patent/PL3194407T3/pl unknown
- 2015-09-17 MY MYPI2017700447A patent/MY186523A/en unknown
- 2015-09-17 ES ES15766800T patent/ES2763344T3/es active Active
- 2015-09-17 CN CN201580050163.3A patent/CN106687464B/zh active Active
- 2015-09-17 HR HRP20192334TT patent/HRP20192334T1/hr unknown
- 2015-09-17 AU AU2015316799A patent/AU2015316799B2/en active Active
- 2015-09-17 EP EP15766800.5A patent/EP3194407B1/en active Active
- 2015-09-17 BR BR112017004035-2A patent/BR112017004035B1/pt active IP Right Grant
- 2015-09-17 PT PT157668005T patent/PT3194407T/pt unknown
- 2015-09-17 SG SG11201701116XA patent/SG11201701116XA/en unknown
-
2017
- 2017-02-09 IL IL250544A patent/IL250544B/en active IP Right Grant
- 2017-02-22 ZA ZA2017/01331A patent/ZA201701331B/en unknown
- 2017-03-14 SA SA517381087A patent/SA517381087B1/ar unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | smyd inhibitors | |
| IL274159A (en) | Heteroaryl compounds for kinase inhibition | |
| ZA201901034B (en) | Macrocycle kinase inhibitors | |
| ZA201700115B (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| PL3218378T3 (pl) | Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych | |
| EP3131900A4 (en) | Heterocyclic kinase inhibitors | |
| IL251784A0 (en) | Bromodomain inhibitors | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| ZA201701841B (en) | Macrocyclic lrrk2 kinase inhibitors | |
| IL241250A0 (en) | Macrocyclic inhibitors of rip2 kinase | |
| ZA201701331B (en) | Macrocyclic rip2 kinase inhibitors | |
| GB201404570D0 (en) | Macrocyclic kinase inhibitors | |
| GB201404555D0 (en) | Macrocyclic kinase inhibitors | |
| GB201519382D0 (en) | Kinase inhibitors | |
| GB201519381D0 (en) | Kinase inhibitors | |
| GB201304714D0 (en) | Macrocyclic RIP2 Kinase inhibitors | |
| AU2014903812A0 (en) | Novel kinase inhibitors i | |
| GB201418154D0 (en) | Inhibitors | |
| GB201409661D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201405532D0 (en) | Novel compounds and their use as Kinase inhibitors |